Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy

AIDS Reviews

Volumn 9, Issue 1, 2007, Pages 3-15

  Mallon, Patrick W G ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiretroviral; HIV; Lipodystrophy; Mitochondria

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN C3; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MITOCHONDRIAL DNA; MITOCHONDRIAL RNA; NELFINAVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEASOME; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; THYMIDINE DERIVATIVE; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BODY FAT; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROTECTION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; CYTOTOXICITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPLICATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME INHIBITION; ETHNICITY; FATTY ACID METABOLISM; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; HAPLOTYPE; HEREDITY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPOATROPHY; LIPODYSTROPHY; LIPOLYSIS; LYMPHOCYTE COUNT; MITOCHONDRIAL TOXICITY; MOLECULAR DYNAMICS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT;

ADIPOCYTES; ANTI-RETROVIRAL AGENTS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LIPID METABOLISM; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34248357883     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352(1):48-62
2. Mallon P, Miller J, Cooper D, Carr A. Prospective evaluation of the effects of ART on body composition in HIV-1-infected men starting therapy. AIDS 2003;17:971-9.
3. Lewis W, Dalakas M. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-22.
4. Brinkman K, Smeitink J, Romijn J, Reiss P. Mitochondrial toxicity induced by NRTI is a key factor in the pathogenesis of ART-related lipodystrophy. Lancet 1999;354:1112-5.
5. Bogner J, Vielhauer V, Beckmann R, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 2001;27:237-44.
6. Dowell F, Flexner C, Kwiterovich P, Lane M. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV PI. J Biol Chem 2000;275:41325-32.
7. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV PI indinavir impairs SREBP-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001;50:1378-88
8. Roche R, Poizot-Martin I, Yazidi C, et al. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 2002;16:13-20.
9. Caron M, Auclair M, Lagathu C, et al. The HIV-1 NRTI stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004;18:2127-36.
10. Domingo P, Matias-Guiu X, Pujol R, et al. Subcutaneous adipocyte apoptosis in HIV-1 PI-associated lipodystrophy. AIDS 1999;13:2261-7.
11. Bastard J, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359:1026-31.
12. Janneh O, Hoggard P, Tjia J, et al. Intracellular disposition and metabolic effects of zidovudine, stavudine and four PI in cultured adipocytes. Antivir Ther 2003;8:417-26.
13. Walker U, Bickel M, Lutke Volksbeck S, et al. Evidence of NRTI-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002;29:117-21.
14. Lenhard J, Furfine E, Jain R, et al. HIV PI block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000;47:121-9.
15. Rudich A, Vanounou S, Riesenberg K, et al. The HIV PI nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001;50:1425-31.
16. Newmeyer D, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. Cell 2003;112: 481-90.
17. Kakuda T. Pharmacology of nucleoside and nucleotide RTI-induced mitochondrial toxicity. Clin Ther 2000;22:685-708.
18. Johnson A, Ray A, Hanes J, et al. Toxicity of antiviral nucleoside analogs and the human mtDNA polymerase. J Biol Chem 2001;276:40847-57.
19. Birkus G, Hitchcock M, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenotovir: comparison with other NRTI. Antimicrob Agents Chemother 2002;46:716-23.
20. Walker U, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of NRTI. AIDS 2002;16:2165-73.
21. Pan-Zhou X, Cui L, Zhou X, Sommadossi J, Darley-Usmar V. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 2000;44:496-503.
22. Setzer B, Schlesier M, Walker U. Effects of didanosine-related depletion of mtDNA in human T-lymphocytes. J Infect Dis 2005;191:848-55.
23. Galluzzi L, Pinti M, Troiano L, et al. Changes in mitochondrial RNA production in cells treated with nucleoside analogs. Antivir Ther 2005;10:191-5.
24. Walker U, Venhoff N, Koch E, Olschewski M, Schneider J, Setzer B. Uridine abrogates mitochondrial toxicity related to NRTI in HepG2 cells. Antivir Ther 2003;8:463-70.
25. Shikuma C, Hu N, Milne C, et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001;15:1801-9.
26. Walker U, Bauerle J, Laguno M, et al. Depletion of mtDNA in liver under ART with didanosine, stavudine, or zalcitabine. Hepatology 2004;39:311-7.
27. De Mendoza C, de Ronde A, Smolders K, et al. Changes in mtDNA copy number in blood cells from HIV-infected patients undergoing ART. AIDS Res Hum Retroviruses 2004;20:271-3.
28. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with NRTI therapy. AIDS 2003;17:1329-38.
29. Pace C, Martin A, Hammond E, Mamotte C, Nolan D, Mallal S. Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther 2003;8:323-31.
30. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. Jama 2002;288:207-15.
31. McComsey G, Paulsen D, Lonergan J, et al. Improvements in lipoatrophy, mtDNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005;19:15-23.
32. Hammond E, Nolan D, James I, Metcalf C, Mallal S. Reduction of mtDNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing NRTI therapy. AIDS 2004;18:815-7.
33. Mallon P, Unemori P, Sedwell R, et al. In vivo, NRTI alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mtDNA. J Infect Dis 2005;191:1686-96.
34. Casula M, Bosboom-Dobbelaer I, Smolders K, et al. Infection with HIV-1 induces a decrease in mtDNA. J Infect Dis 2005;191:1468-71.
35. Miura T, Goto M, Hosoya N, et al. Depletion of mtDNA in HIV-1-infected patients and its amelioration by ART. J Med Virol 2003; 70:497-505.
36. Reiss P, Casula M, de Ronde A, Weverling G, Goudsmit J, Lange J. Greater and more rapid depletion of mtDNA in blood of patients treated with dual (zidovudine + didanosine or zidovudine + zalcitabine) vs. single (zidovudine) NRTI. HIV Med 2004;5:11-4.
37. Casula M, Weverling G, Wit F, et al. Mitochondrial DNA and RNA increase in PBMC from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. J Infect Dis 2005;192:1794-800.
38. Cherry C, Gahan M, McArthur J, Lewin S, Hoy J, Wesselingh S. Exposure to dideoxynucleosides is reflected in lowered mtDNA in subcutaneous fat. J Acquir Immune Defic Syndr 2002;30:271-7.
39. Hoy J, Gahan M, Carr A, et al. Changes in mtDNA in PBMC from HIV-intected patients with lipoatrophy randomized to receive abacavir. J Infect Dis 2004;190:688-92.
40. Bartley P, Westacott L, Boots R, et al. Large hepatic mtDNA deletions associated with L-lactic acidosis and HAART. AIDS 2001;5:419-20.
41. Miro O, Gomez M, Pedrol E, Cardellach F, Nunes V, Casademont J. Respiratory chain dysfunction associated with multiple mtDNA deletions in ART-related lipodystrophy. AIDS 2000;14:1855-7.
42. Zaera M, Miro O, Pedrol E, et al. Mitochondrial involvement in ART-related lipodystrophy. AIDS 2001;15:1643-51.
43. Ingman M, Kaessmann H, Paabo S, Gyllensten U. Mitochondrial genome variation and the origin of modern humans. Nature 2000;408:708-13.
44. Hulgan T, Haas D, Haines J, et al. Mitochondrial haplogroups and peripheral neuropathy during ART: an adult AIDS clinical trials group study. AIDS 2005;19:1341-9.
45. Shimano H. SREBP: transcriptional regulators of lipid synthetic genes. Prog Lipid Res 2001;40:439-52.
46. Kersten S. Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2001;2:282-6.
47. Inoue J, Kumagai H, Terada T, Maeda M, Shimizu M, Sato R. Proteolytic activation of SREBPs during adipocyte differentiation. Biochem Biophys Res Commun 2001;283:1157-61.
48. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, PPARγ co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with HAART. AIDS 2003;17:1753-62.
49. Miserez A, Muller P, Spaniol V. Indinavir inhibits SREBP-1c-dependent lipoprotein lipase and fatty acid synthase gene activations. AIDS 2002;16:1587-94.
50. Riddle T, Kuhel D, Woollett L, Fichtenbaum C, Hui D. HIV PI induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated SREBP in the nucleus. J Biol Chem 2001;276:37514-9.
51. Nguyen A, Gagnon A, Angel J, Sorisky A. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS 2000;14:2467-73.
52. Shimomura I, Hammer R, Richardson J, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998;12:3182-94.
53. Tamori Y, Masugi J, Nishino N, Kasuga M. Role of PPARγ in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 2002;51:2045-55.
54. Gavrilova O, Haluzik M, Matsusue K, et al. Liver PPARγ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003;278:34268-76.
55. Vega R, Huss J, Kelly D. The co-activator PGC-1 cooperates with PPARα in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000; 20:1868-76.
56. Klaus S. Functional differentiation of white and brown adipocytes. Bioessays 1997;19:215-23.
57. Mallon P, Wand H, Law M, Miller J, Cooper D, Carr A. Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia. J Acquir Immune Defic Syndr 2005;38:156-62.
58. Gan S, Samaras K, Thompson C, et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV PI-related lipodystrophy. Diabetes 2002;51:3163-9.
59. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter W. Differentiating hyperlipidemia associated with ART. AIDS 2003; 17:189-94.
60. Riddler S, Smit E, Cole S, et al. Impact of HIV infection and HAART on serum lipids in men. Jama 2003;289:2978-82.
61. Miller N. Plasma lipoproteins, lipid transport, and atherosclerosis: recent developments. J Clin Pathol 1979;32:639-50.
62. Reeds D, Mittendorfer B, Patterson B, Powderly W, Yarasheski K, Klein S. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab 2003;285:E490-7.
63. Schmitz M, Michl C, Walli R, et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr 2001;26:225-35.
64. Noor M, Lo J, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15:F11-8.
65. Dube M, Edmondson-Melancon H, Qian D, Aqeel R, Johnson D, Buchanan T. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr 2001;27:130-4.
66. Noor M, Parker R, O'Mara E, et al. The effects of HIV PI atazanavir and lopinavir/r on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004;18:2137-44.
67. Purnell J, Zambon A, Knopp R, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51-7.
68. Lenhard J, Croom D, Weiel J, Winegar D. HIV PI stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000; 20:2625-9.
69. Lai C, Parnell L, Ordovas J. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol 2005;16:153-66.
70. Rimland D, Guest U, Hernandez I, Del Rio C, Le N, Brown W. ART in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins. HIV Med 2005;6:326-33.
71. Bonnet E, Ruidavets J, Tuech J, et al. Apolipoprotein CIII and E-containing lipoparticles are markedly increased in HIV-infected patients treated with PI: association with the development of lipodystrophy. J Clin Endocrinol Metab 2001;86:296-302.
72. Tarr P, Taffe P, Bleiber G, et al. Modeling the influence of APCC3, APOE, and TNF polymorphisms on the risk of ART-associated lipid disorders. J Infect Dis 2005;191:1419-26.
73. Fauvel J, Bonnet E, Ruidavets J, et al. An interaction between ApoCIII variants and PI contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001;15:2397-406.
74. Foulkes A, Wohl D, Frank I, et al. Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on ART. PLoS Med 2006;3:e52.
75. Hirano Y, Yoshida M, Shimizu M, Sato R. Direct demonstration of rapid degradation of nuclear SREBP by the ubiquitin-proteasome pathway. J Biol Chem 2001;276:36431-7.
76. Liang J, Distler O, Cooper D, et al. HIV PI protect apolipoprotein B from degradation by the proteasome: a potential mechanism for PI-induced hyperlipidemia. Nat Med 2001;7:1327-31.
77. Kelleher A, Booth B, Sewell A, et al. Effects of retroviral PI on proteasome function and processing of HIV-derived MHC class I-restricted CTL epitopes. AIDS Res Hum Retroviruses 2001;17:1063-6.
78. Nerurkar F, Shikuma C, Nerurkar V. SREBP and reactive oxygen species: potential role in HAART-associated lipodystrophy. Clin Biochem 2001;34:519-29.
79. Noor M, Seneviratne T, Aweeka F, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002;16:F1-8.
80. Murata H, Hruz P, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002;16:859-63.
81. Brown T, Li X, Cole S, et al. Cumulative exposure to NRTI is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005;19:1375-83.
82. Sanchez-Margalet V, Martin-Romero C, Gonzalez-Yanes C, Goberna H, Rodriguez-Bano J, Muniain M. Leptin receptor (Ob-R) expression is induced in PBMC by in vitro activation and in vivo in HIV-infected patients. Clin Exp Immunol 2002;129:119-24.
83. Nagy D, Tsiodras S, Martin L, et al. HIV-1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003;36:795-802.
84. Estrada V, Serrano-Rios M, Martinez Larrad M, et al. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with ART. J Acquir Immune Defic Syndr 2002;29:32-40.
85. Oral E, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002;346:570-8.
86. Fantuzzi G. Adipose tissue, adipokines, and inflammation. In: J Allergy Clin Immunol; 2005;911-9: [quiz 20].
87. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002;8:1288-95.
88. Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen B. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004;135:273-9.
89. Tong Q, Sankale J, Hadigan C, et al. Regulation of adiponectin in HIV-intected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003;88:1559-64.
90. Hadigan C, Yawetz S, Thomas A, Havers F, Sax P, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004;140:786-94.
91. Gavrila A, Hsu W, Tsiodras S, et al. Improvement in HAART-induced metabolic syndrome by treatment with pioglitazone but not with tenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin Infect Dis 2005;40:745-9.
92. Murata H, Hruz P, Mueckler M. The mechanism of insulin resistance caused by HIV PI therapy. J Biol Chem 2000;275:20251-4.
93. Kahn S, Prigeon R, Schwartz R, et al. Obesity, body fat distribution, insulin sensitivity and Islet β-cell function as explanations for metabolic diversity. J Nutr 2001;131:354-60S.
94. Garg A, Stray-Gundersen J, Parsons D, Bertocci L. Skeletal muscle morphology and exercise response in congenital generalized lipodystrophy. Diabetes Care 2000;23:1545-50.
95. Wurtz R, Ceaser S. Adipose redistribution in HIV-seropositive patients: association with CD4 response. Clin Infect Dis 2000;31:1497-8.
96. Dube M, Parker R, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005;19:1807-18.
97. Weisberg S, McCann D, Desai M, Rosenbaum M, Leibel R, Ferrante A. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-808.
98. Ferre P. The biology of PPAR: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004;53(Suppl 1):S43-50.
99. Ledru E, Christeff N, Patey O, de Truchis P, Melchior J, Gougeon M. Alteration of TNFα T-cell homeostasis following potent ART: contribution to the development of HIV-associated lipodystrophy syndrome. Blood 2000;95:3191-8.
100. Mynarcik D, McNurlan M, Steigbigel R, Fuhrer J, Gelato M. Association of severe insulin resistance with both loss of limb fat and elevated serum TNF receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000;25:312-21.
101. Jiang C, Ting A, Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-6.
102. Sutinen J, Kannisto K, Korsheninnikova E, et al. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in HAART-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004;286:E941-9.
103. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomized, double-blind, placebo-controlled trial. Lancet 2004;363:429-38.